Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLAT: Steroid vs Steroid + Mycophenolate Mofetil for Immune-Related Hepatitis from ICIs
jRCT2031250564Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of mycophenolate mofetil in Immune-Related Hepatitis (irH), Drug-induced hepatitis (DILI) and Nonhematologic neoplasms (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary: ALT reduction rate on Day 7. Started Dec 2025; status: recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
Immune-Related Hepatitis (irH)Drug-induced hepatitis (DILI)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250564.